About the CHANCES Study

Ovarian Cancer Individuals have a significantly higher risk of developing Therapy-related myeloid neoplasms (TMNs) than other cancers. The Clonal HemAtopoeisis iN CancEr Survivors (CHANCES) study wants to research and better understand the connection between ovarian and other solid cancers, its treatments, and the development of serious secondary cancers (TMNs).

Dr. Elizabeth Swisher is the Principal Investigator for this study and is a gynecologic oncologist, UW School of Medicine professor and Co-Leader of the Breast and Ovarian Cancer Research Program at the Fred Hutchison/University of Washington Cancer consortium.

Eligibility Criteria

  • >18 years of age

  • Located in the United States

  • And at least ONE of the following:

    • Ovarian cancer survivors with a history of or plan to complete at least 5 cycles of carboplatin chemotherapy (can be on or off treatment)

    • Have another solid tumor with 4 or more months of PARP inhibitor exposure (past or current)

    • Have another solid tumor and clonal hematopoiesis, cytopenia of uncertain significance, or therapy induced AML (acute myeloid leukemia) or MDS (myelodysplastic syndrome)

Eligible Participant Research Commitment*

  • Screening and eligibility confirmation

  • Consent discussion with research team

  • Baseline questionnaire

  • Initial baseline blood draw

  • Check-in questionnaire every 12 months for 2 years

  • Serial blood draw every 12 months for 2 years for all participants

  • Final blood draw at 2 years

*Study is expected to last 5 years and participants will be followed for 2 years

For more information please email us at swisherlabrc@uw.edu to connect with our research coordinators

Frequently Asked Questions

Prescreen